Sugi Predict

Sugi Predict / Compounds / SCHEMBL15056409

SCHEMBL15056409

SCHEMBL15056409

CC(=O)Oc1ccc(OC(C)C)c(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.46
▸ LMNA P02545 3/20 0.43
▸ XDH P47989 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ BACE1 P56817 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ RORC P51449 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ CFD P00746 1/20 0.40
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40
▸ TUBA3C P0DPH7 1/20 0.40
▸ TUBA1B P68363 1/20 0.40
▸ TUBA4A P68366 1/20 0.40
▸ TUBB4B P68371 1/20 0.40
▸ TUBB3 Q13509 1/20 0.40
▸ TUBB2A Q13885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543743 0.90 KDM4E (0.46) KDM4ELMNAMAPTMAPK1BACE1
SCHEMBL9477989 0.86 KDM4E (0.56) KDM4ELMNACYP3A4MAPTMAPK1
SCHEMBL28373416 0.86 ALDH1A1 (0.44) KDM4ELMNAXDHALDH1A1RORC
SCHEMBL286726 0.84 ALDH1A1 (0.58) KDM4ELMNACYP3A4MAPTMAPK1
SCHEMBL3688114 0.83 XDH (0.40) LMNAXDHACHEALDH1A1RORC
SCHEMBL3496650 0.78 KDM4E (0.44) KDM4ELMNACYP3A4MAPTMAPK1
SCHEMBL9280624 0.77 BACE1 (0.57) KDM4ELMNAMAPTMAPK1BACE1
SCHEMBL3931086 0.77 ALDH1A1 (0.52) KDM4ELMNAMAPTALDH1A1TUBB1
SCHEMBL31063385 0.77 ALDH1A1 (0.52) KDM4ELMNAMAPTALDH1A1TUBB1
SCHEMBL3948122 0.76 LMNA (0.59) KDM4ELMNACYP3A4MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3844151-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-08-23 — — EP disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 — — CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 — — US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 — — EP disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
EP-2794563-B1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2017-02-22 — — EP disclosed
CN-104011021-B heterocyclic derivatives and their use as prostaglandin D2 receptor modulators 埃科特莱茵药品有限公司 2016-08-24 — — CN disclosed
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 — — US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 — — US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 — — EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 KDM4E 4188/4885LMNA 1760/4885XDH 1359/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS KDM4E 3689/4885LMNA 2991/4885XDH 4517/4885
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS KDM4E 3689/4885LMNA 2991/4885XDH 4517/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS KDM4E 3689/4885LMNA 2991/4885XDH 4517/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS KDM4E 3689/4885LMNA 2991/4885XDH 4517/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS KDM4E 3689/4885LMNA 2991/4885XDH 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.